Tracking the Expansion Activities of Contract Service Providers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tracking the Expansion Activities of Contract Service Providers
A review of recent moves of CDMOs and CMOs


Pharmaceutical Technology
pp. s22-s28

High-potency additions
Companies also have made investments to increase capacity for high-potency forms. In February 2013, Baxter International’s BioPharma Solutions business began an approximately 1750-m2 capacity expansion at the company’s fill-finish cytotoxic contract-manufacturing facility in Halle (Westfalen), Germany. This expansion follows previous expansions in Halle in 2007 and 2011. In April 2013, Goodwin Technology and Coldstream Laboratories agreed to develop and manufacture high-potency, highly cytotoxic materials, such as small molecules, protein toxins, cytotoxic ADCs, and other bioconjugates. Goodwin will use Coldstream’s cGMP platform of services, including analytical testing, formulation, liquid or lyophilized fill-finish, storage, and shipment of manufactured highly potent bioconjugates. In May 2013, Penn Pharma successfully completed the first batch of coated tablets at its new contained manufacturing facility in South Wales, UK. The facility is designed for the clinical and commercial manufacture of tablets and capsules. Penn invested 14 million ($21 million) for the new 15,000-ft2 facility, which includes the capability to handle potent compounds. In July 2013, the company announced an additional 3-million investment ($4.6 million).

Other moves
Other companies are making moves as well. Bend Research expanded its GMP analytical capabilities with the addition of onsite stability storage and additional GMP testing capabilities for clinical-trial material supply. The company recently added instrumentation to its existing suite of GMP-qualified analytical equipment, including a differential scanning calorimeter and particle-size analyzer. In May 2013, Halo Pharma took a minority ownership position in and established a formal collaboration with the drug-formulation and development company Altus Formulation. Capsugel launched its new LIPIDEX technology platform that integrates its lipid, liquid, and semisolid fill technologies, product-development capabilites, and commercial-manufacturing infrastructure. The platform is part of Capsugel’s Dosage Form Solutions business unit.

Earlier this year, Azaya Therapeutics, an oncology company developing cancer treatments through its nanotechnology platform, launched Parexo Labs, a CDMO providing contract chemical testing and liposomal manufacturing services. In April 2013, the fine-chemicals company Ajinomoto acquired the CDMO Althea Technologies, which offers protein formulation and fill-finish services as well as contract biologics manufacturing. Aptuit launched a translational strategy (i.e., Complementary Vision) for chemistry, manufacturing and control (CMC) services. It is an approach that encompasses all the services that precede and follow CMC in the target product profile: API development and manufacture; qualitative/quantitative chemical, physical and biopharmaceutical characterization of actives and dosage forms; dosage-form design; development and manufacturing for preclinical and clinical dosing; and the development, manufacturing and testing of inhaled products such as dry powder inhalers.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here